Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Genmab is a leader in the antibody therapeutics space, underpinned by its innovative and proprietary technology platforms (DuoBody®, HexaBody®) that have yielded a portfolio of approved, revenue-generating products and a deep clinical pipeline.</li>
  <li>The company's hybrid business model, which combines in-house development with strategic, high-value partnerships with major pharmaceutical companies like AbbVie, Pfizer, and Janssen, diversifies risk and provides significant, recurring royalty and milestone revenue.</li>
  <li>Future growth is contingent on the continued success of key partnered products like DARZALEX, the successful commercialization of new therapies such as Epkinly and Tivdak, and the progression of its extensive oncology-focused pipeline.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Genmab is a leader in the antibody therapeutics space, underpinned by its innovative and proprietary technology platforms (DuoBody®, HexaBody®) that have yielded a portfolio of approved, revenue-generating products and a deep clinical pipeline.
  The company's hybrid business model, which combines in-house development with strategic, high-value partnerships with major pharmaceutical companies like AbbVie, Pfizer, and Janssen, diversifies risk and provides significant, recurring royalty and milestone revenue.
  Future growth is contingent on the continued success of key partnered products like DARZALEX, the successful commercialization of new therapies such as Epkinly and Tivdak, and the progression of its extensive oncology-focused pipeline.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Denmark

Genmab A/S operates as a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Genmab A/S (GEN DC)

Primer: Genmab A/S (GEN DC) - Oct 2025

Genmab is a leader in the antibody therapeutics space, underpinned by its innovative and proprietary technology platforms (DuoBody®, HexaBody®)...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)